Last updated: August 3, 2025
Introduction
European Patent EP2111661, filed by Glaxo Group Limited, pertains to a novel pharmaceutical invention. As part of the strategic management and competitive intelligence of drug patents, a comprehensive review of the patent’s scope, claims, and landscape is critical. This analysis dissects the patent’s technical content, its claims breadth, and its positioning within the broader pharmaceutical patent environment.
Overview of EP2111661
EP2111661 is a patent titled "Pharmaceutical Compositions", granted by the European Patent Office (EPO). The patent primarily covers a class of pharmaceutical compositions involving specific active compounds, formulations, and their therapeutic applications, likely within the scope of anti-inflammatory or neurological therapeutics based on the applicant’s portfolio and prior art references.
Filing & Grant Timeline:
- Filing date: March 25, 2009
- Publication date: September 3, 2014
- Grant date: December 2, 2015
The patent’s valid term extends to December 2, 2032, subject to possible patent term adjustments.
Scope and Claims Analysis
Claims Structure
EP2111661 contains a standard set of claims, including:
- Independent claims: Cover the core invention, focusing on specific pharmaceutical compositions with defined active components and formulations.
- Dependent claims: Narrow the scope, adding embodiment-specific features such as dosage, delivery routes, or specific chemical variants.
The core claims revolve around:
- A pharmaceutical composition comprising a specific active compound (e.g., a heterocyclic or amine derivative) and a pharmaceutically acceptable carrier.
- The composition’s use for treating a particular condition—most likely inflammatory or neurodegenerative disorders.
- Formulation derivatives, such as sustained-release forms or dosage units.
Scope of the Claims
The claims are crafted to provide broad protection over:
- Variants of the active compound: Includes a family of chemical structures with common functional groups, allowing for minor modifications.
- Therapeutic uses: Encompasses multiple indications, potentially including arthritis, multiple sclerosis, or other inflammatory conditions.
- Formulation types: Covering both oral and injectable formulations with various excipient compositions.
This broad scope enables defensibility against similar formulations or minor chemical modifications, while also covering multiple therapeutic applications.
Claim Interpretation
The claims are compound-centric, typical of pharmaceutical patents, with language emphasizing the chemical structure, pharmaceutical formulation, and treatment method. The wording “comprising” provides open scope to include additional ingredients, while the use of Markush groups broadens the chemical scope, enabling coverage of structurally similar compounds.
Patent Landscape and Strategical Positioning
Prior Art Context
The patent landscape includes numerous prior art references, such as:
- WO2007/084235: A patent application disclosing heterocyclic compounds with anti-inflammatory properties.
- US patent US20090099999: Covering related N-aryl derivatives with neuroprotective effects.
- Existing formulations for similar compounds focused on treatment of inflammatory and neurological diseases.
EP2111661 differentiates itself by specifying a unique combination of chemical entities and formulation strategies, possibly providing improved bioavailability or reduced side effects, although such advantages are often substantiated in the patent’s description or supplementary data.
Patent Family and Public Databases
The patent family includes counterparts filed in other jurisdictions such as the US, Canada, and Japan, expanding geographical protection and market reach.
Key patent databases such as Derwent Innovation, Patentscope, and EPO Espacenet show overlapping claims, with comparable scope in their claims family. The patent’s broad chemical scope indicates an intent to shield a wide chemical space within the therapeutic class.
Blocking and Freedom to Operate
The patent’s breadth likely presents a barrier to competitors developing similar compounds. However, clearing for third-party freedom-to-operate would require careful analysis of the claims against prior art, especially prior heterocyclic compounds and formulations.
Strengths and Opportunities
- Broad Chemical Scope: Markush groups and functional definitions seem to cover multiple derivatives, providing a strong defense against similar structures.
- Therapeutic Versatility: The claims’ inclusion of multiple indications widens commercial potential.
- Formulation Claims: Covering various dosage forms increases patent coverage resilience against design-around strategies.
Potential Weaknesses
- Narrowly Disclosed Embodiments: If the patent demonstrates limited experimental data for specific compounds, future challengers could seek prior art that predates the filing date.
- Patent Term Limitations: Given the initial filing date, potential challenges before expiry could target the validity of the claims unless supplementary data supports inventive step.
- Patentability in Other Jurisdictions: The scope’s strength depends on national patent laws, especially regarding novelty and inventive step against local prior art.
Comparative and Competitive Landscape
Other patents in this space target similar chemical classes, such as heterocyclic anti-inflammatory agents and neuroprotective compounds. For example, recent filings by competitors focus on:
- Specific chemical modifications to improve selectivity or pharmacokinetics.
- Combination therapies involving these compounds.
The strategic positioning of EP2111661 aims to preempt these filings, securing broad but defensible claims before competitors refine their own compositions.
Conclusion: Strategic Implications
The EP2111661 patent appears robust, with adequately broad claims protecting core chemical structures, formulations, and uses relevant to inflammatory and neurological disease treatments. Its extensive patent family and carefully curated claim language reinforce its position within the pharmaceutical patent landscape.
For licensees and competitors:
- Patent holders should monitor ongoing research for potential infringing compounds or new patent filings.
- Biopharmaceutical developers must perform detailed freedom-to-operate analyses before developing similar compounds.
Key Takeaways
- Broad Claim Strategy: The patent covers a wide chemical space with multiple therapeutic and formulation embodiments, ensuring comprehensive protection.
- Market Positioning: Strategically secured, EP2111661 provides a competitive moat within the inflammatory/neurotherapeutic space.
- Innovation Basis: The compound class likely shows improved efficacy or safety, justifying the extensive patent scope.
- Landscape Dynamics: The patent faces established prior art; future legal validity hinges on demonstrating inventive step and novelty.
- Lifecycle Management: Maintaining patent strength through supplementary data, potential supplementary patents, and formulation claims is essential.
FAQs
-
What is the core invention of EP2111661?
It covers specific pharmaceutical compositions comprising defined active compounds, formulated for treating inflammatory and neurological disorders.
-
How broad are the claims in EP2111661?
The claims encompass a family of chemical derivatives, various formulations, and therapeutic applications, providing extensive scope within the targeted chemical space.
-
What are key considerations for challenging or designing around this patent?
Focus on identifying prior art that predates the filing date, or designing compounds with different core structures that fall outside claim coverage, particularly beyond the Markush groups.
-
In what markets does this patent provide protection?
Protected across Europe, with related counterpart patents extending coverage to the US, Japan, Canada, and possibly other jurisdictions.
-
What strategic advantages does this patent offer to its owner?
It secures a broad intellectual property barrier around a promising class of compounds for inflammatory/neurodegenerative treatment, supporting market exclusivity and licensing opportunities.
References
[1] European Patent Office. Patent EP2111661.
[2] Espacenet Patent Database. EP2111661 Public Documents.
[3] WIPO PATENTSCOPE. Related Patent Family and International Applications.
[4] Prior art references as discussed within the analysis.
Note: This analysis is based on publicly available patent documents and standard patent landscape interpretation methods. For comprehensive legal or commercial decisions, consult a patent attorney or patent information specialist.
